Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

Barcelona 8035

5 studies enrolling now · 10 studies all time

What they study most

Advanced Malignant Neoplasm, Advanced Solid Tumor, Breast Cancer, Cervical Cancer, Clear Cell RCC, Colorectal Cancer, EGFR/HER2 Exon 20 Insertion Mutation, ER/PR Positive Breast Cancer, ER/PR(+), Her2(-) Breast Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer

Studies at this site

• A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors — Recruiting now
• A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer — Recruiting now
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — Recruiting now
• First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations — Recruiting now
• A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors — Running, not enrolling
• First-in-Human Study of TAK-280 in Participants With Solid Tumors — Stopped early
• A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors — Completed
• ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer — Running, not enrolling
• Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer — Completed